January 9, 2026 | Sarasota
Calcification of the aortic valve is the leading cause of heart valve disease in older adults, and currently, there are no approved medications to slow its progression. Sarasota Memorial’s Kolschowsky Research and Education Institute is working to change that.
The new KATALYST-AV trial, sponsored by Kardigan, Inc aims to evaluate whether the investigational medication ataciguat can slow the buildup of calcium in the aortic valve in adults with moderate calcific aortic valve stenosis (CAVS)…